logo-loader
viewApple Inc.

Apple stock jumps on JP Morgan's price-target bump, increased iPhone sales projections

The firm bolstered its price target to $265 from $243 and maintained its Overweight rating

Two iPhone 11s
JP Morgan expects 1 million more iPhones to be sold this quarter than previously expected and 3 million more in the first quarter of 2020

Apple Inc's (NASDAQ:AAPL) stock rose Monday after JP Morgan upped its price target for the company based on stronger-than-expected iPhone sales.

The firm bolstered its price target to $265 from $243 and maintained its Overweight rating on Apple, according to a report from CNBC.

In an analyst note, JP Morgan wrote that it anticipates 1 million more iPhone sales this quarter than previously expected and 3 million more in the first quarter of 2020.

"We are modestly raising our iPhone volume forecasts and expect investor sentiment on AAPL shares to improve materially given the firm’s ability to drive upward revision to volume expectations despite the 2019 product cycle largely considered to be a muted one," JP Morgan said.

READ: Apple wants its upcoming original movies to get major theatrical debut before TV+ users stream them

Apple shares ended 2.4% higher Monday at $223.97.

Another key to the increased price target is the rollout of 5G, which JP Morgan expects Apple to unveil in its products in September 2020. 

"In addition to a rise in volume expectations for 2019 product cycle, we are also increasing calendar 2020/2021 volume expectations led by stronger adoption of 5G enabled iPhones,” the firm said. 

Specifically, it expects Apple to sell 198 million 5G phones in 2020 and 200 million in 2021.

—Updated to include closing price—

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Apple Inc.

Price: 324.95 USD

NASDAQ:AAPL
Market: NASDAQ
Market Cap: $1.42 trillion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharma CEO confident as he looks ahead to new Traumakine study

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen caught up with Proactive London's Andrew Scott soon after announcing they've amended the protocol for a second phase III study of its drug for acute respiratory distress syndrome (ARDS). The tweak's in response to...

1 hour, 23 minutes ago

2 min read